SCHEMBL334783

SCHEMBL334783

O=c1ccccn1CCCC1CO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.40
PSMB1 P20618 1/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PLD1 Q13393 1/20 0.38
NPC1 O15118 1/20 0.38
MITF O75030 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DHFR P00374 1/20 0.37
PSMB5 P28074 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PREP P48147 1/20 0.35
FAP Q12884 1/20 0.35
TSHR P16473 1/20 0.34
HTR7 P34969 1/20 0.34
DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335903 0.90 L3MBTL1 (0.42) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL15122410 0.80 DHFR (0.49) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL9752675 0.78 L3MBTL1 (0.51) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL9394796 0.78 L3MBTL1 (0.51) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL9752728 0.77 L3MBTL1 (0.50) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL9752571 0.77 L3MBTL1 (0.50) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL9752719 0.77 L3MBTL1 (0.50) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL9752595 0.74 L3MBTL1 (0.55) L3MBTL1PSMB1POLBNPSR1PLD1
SCHEMBL571018 0.72 CYP1A2 (0.56) L3MBTL1LMNARAB9ASMN1; SMN2TSHR
SCHEMBL6536824 0.72 PSMB1 (0.47) L3MBTL1PSMB1POLBNPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 L3MBTL1 2853/4885PSMB1 3449/4885POLB 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.